<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714190</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-007</org_study_id>
    <nct_id>NCT04714190</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression</brief_title>
  <official_title>Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare&#xD;
      RC48-ADC to physician choice standard treatment in participants with human epidermal growth&#xD;
      factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase III multi-center, randomized, open-label, parallel control study to&#xD;
      evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal&#xD;
      antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of HER2-overexpression&#xD;
      locally advanced or metastatic gastric cancer. The HER2-overexpression is defined as: the&#xD;
      HER2 IHC 3+ or 2+, regardless of FISH status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS), evaluated by the investigator</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective remission rate (ORR)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of relief (DOR)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor progression time (TTP)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>HER2 Overexpressing Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <description>2.5 mg/kg IV every 2 weeks</description>
    <arm_group_label>RC48-ADC</arm_group_label>
    <other_name>Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>Administered according to label, as one option for Physician's Choice (determined before randomization)</description>
    <arm_group_label>Physician's Choice</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride Injection</intervention_name>
    <description>Administered according to label, as one option for Physician's Choice (determined before randomization)</description>
    <arm_group_label>Physician's Choice</arm_group_label>
    <other_name>CAMPTO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate Tablets</intervention_name>
    <description>Administered according to label, as one option for Physician's Choice (determined before randomization)</description>
    <arm_group_label>Physician's Choice</arm_group_label>
    <other_name>Aitan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary agreement to provide written informed consent.&#xD;
&#xD;
          -  Male or female, Age ≥ 18 years.&#xD;
&#xD;
          -  Predicted survival ≥ 12 weeks.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.&#xD;
&#xD;
          -  All female subjects will be considered to be of child-bearing potential unless they&#xD;
             are postmenopausal, or have been sterilized surgically.Female subjects of&#xD;
             child-bearing potential must agree to use two forms of highly effective contraception.&#xD;
             Male subjects and their female partner who are of child-bearing potential must agree&#xD;
             to use two forms of highly effective contraception.&#xD;
&#xD;
          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions&#xD;
             specified in this protocol.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  All subjects must have inoperable, advanced or metastatic gastric or or&#xD;
             gastroesophageal adenocarcinoma&#xD;
&#xD;
          -  Have had progression or intolerance following receipt of at least two systemic&#xD;
             chemotherapy for advanced or metastatic disease.&#xD;
&#xD;
          -  The HER2 IHC test result is IHC 2+ or IHC 3+, the subject's previous test results&#xD;
             (confirmed by the investigator) or the research center's test results are acceptable;&#xD;
             the subject can provide the Specimen of primary or metastatic tumor for HER2&#xD;
             review/judgment.&#xD;
&#xD;
          -  HER2 classic positive (definition: IHC3+ or IHC2+FISH+) and patients who have&#xD;
             previously failed standard treatment&#xD;
&#xD;
          -  According to the RECIST 1.1 standard, there is at least one measurable lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE&#xD;
             Conjugate For Injection.&#xD;
&#xD;
          -  History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to&#xD;
             trial treatment.&#xD;
&#xD;
          -  History of major surgery within 4 weeks of planned start of trial treatment.&#xD;
&#xD;
          -  Has received a live virus vaccine within 4 weeks of planned start of trial treatment.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  History of other malignancy within the previous 5 years, except for appropriately&#xD;
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with&#xD;
             a similar curative outcome as those mentioned above.&#xD;
&#xD;
          -  Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Fang, PhD</last_name>
    <phone>010-58075561</phone>
    <email>jianminfang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>010-53806898</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqun Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luhe Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Yan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingjiang Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial Tumor Hospital</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shan Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengde Medical College</name>
      <address>
        <city>Chengde</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingshan Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Three Gorges Hospital Affiliated to Chongqing University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanfeng Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirong Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhong Deng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Qiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie'er Ying</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifu He</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyin Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meili Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changzheng Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical College</name>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Jining City</name>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Tumor Hospital</name>
      <address>
        <city>Linyi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drum Tower Hospital Affiliated to Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Wei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianwei Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongqian Shu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao University Hospital</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wensheng Qiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianbao Zhan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianshu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingdong Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruilian Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mudan Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guohua Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Airong Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huazhong University of Science Tongji Hospital, Tongji Medical College</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enxiao Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiayi Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qinghai University</name>
      <address>
        <city>Xining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junhui Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qinghai Provincial People's Hospital</name>
      <address>
        <city>Xining</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujuan Qi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinxiang Medical College</name>
      <address>
        <city>Xinxiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liuzhong Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu Province</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xizhi Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangming Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suxia Luo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RC48-ADC</keyword>
  <keyword>HER2 overexpression</keyword>
  <keyword>Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

